News Daily News New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration L.A. McKeown December 18, 2018
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2018 Shelley Wood November 30, 2018
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis Caitlin E. Cox November 13, 2018
Presentation AHA 2018 PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure Presenter: Eric J Velazquez November 12, 2018
News Conference News AHA 2018 Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study Shelley Wood November 11, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Daily News Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors L.A. McKeown October 30, 2018
News Conference News TCT 2018 OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients Todd Neale September 24, 2018
News Daily News Aspirin Falters Yet Again in Primary Prevention: ASPREE Michael O'Riordan September 17, 2018
News Daily News Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’ Todd Neale September 13, 2018
Presentation ESC 2018 Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results Presenter: Alex C. Spyropoulos August 27, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2018 Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61 Michael O'Riordan August 26, 2018
News Conference News ESC 2018 CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD Shelley Wood August 25, 2018
News Daily News In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check Caitlin E. Cox August 15, 2018
News Daily News New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients Michael O'Riordan August 13, 2018
News Daily News SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function Todd Neale July 02, 2018
News Daily News NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests Todd Neale June 21, 2018